STOCK TITAN

I-Mab SEC Filings

IMAB Nasdaq

Welcome to our dedicated page for I-Mab SEC filings (Ticker: IMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing I-Mab’s immuno-oncology disclosures is no small task. Each study update, milestone payment, or safety signal can span dozens of pages, leaving investors hunting for the data that moves the stock. That’s why this page brings every filing—from the I-Mab annual report 10-K simplified to the I-Mab quarterly earnings report 10-Q filing—into one searchable hub. Stock Titan’s AI continuously reviews new documents, turning dense text into plain-English bullet points so you get I-Mab SEC filings explained simply.

Want to spot insider sentiment? Our dashboard highlights I-Mab insider trading Form 4 transactions within minutes of release and sends alerts on I-Mab Form 4 insider transactions real-time. Need fast context on pipeline shifts? The platform tags each I-Mab 8-K material events explained, linking drug-specific updates to trial registries. For capital structure or board changes, the I-Mab proxy statement executive compensation section breaks down pay packages, option grants, and voting matters you’ll actually care about.

By understanding I-Mab SEC documents with AI, professionals can quickly run I-Mab earnings report filing analysis, monitor I-Mab executive stock transactions Form 4, and track cash runway all in one place.

  • AI-powered summaries that surface trial catalysts and risk factors
  • Real-time EDGAR feeds for every form type
  • Clickable tables that compare quarter-over-quarter R&D spend

Skip the scroll; access the insights that drive decisions before the market prices them in.

Filing
Rhea-AI Summary

I-Mab (IMAB) reports follow-up details on its Greater China divestiture and related equity interests in TJBio Hangzhou. The company completed an equity transfer that converted a former wholly owned subsidiary into an affiliate and received contingent consideration of up to $80 million (RMB equivalent) tied to future regulatory and sales milestones. Concurrently the group invested $19.0 million in TJBio Hangzhou's Series C and, after repurchases and the Series C investment, held approximately 15% ownership as of December 31, 2024, with no change through June 30, 2025.

I-Mab records an estimated equity value for TJBio Hangzhou of $34.5 million and an estimated put right liability valued at $2.0 million. The company previously expected potential repurchase obligations in the $30–35 million range, which were later addressed through repurchase agreements. As part of a January 2025 strategic reprioritization, I-Mab paused internal development of uliledlimab pending Phase 2 data from TJBio Hangzhou. The filing also notes expected near-term decreases in R&D and administrative expenses due to the divestiture and internal restructuring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.08%
Tags
current report
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus

FAQ

What is the current stock price of I-Mab (IMAB)?

The current stock price of I-Mab (IMAB) is $4.37 as of October 7, 2025.

What is the market cap of I-Mab (IMAB)?

The market cap of I-Mab (IMAB) is approximately 501.4M.
I-Mab

Nasdaq:IMAB

IMAB Rankings

IMAB Stock Data

501.41M
78.65M
21.43%
20%
2.43%
Biotechnology
Healthcare
Link
United States
Rockville